Tyra Biosciences, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Tyra Biosciences, Inc. (TYRA) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $74.40 million as of 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-05-13
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $74.40M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $75.80M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $71.50M.
- 2025-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $56.30M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount as first filed |
|---|---|---|
| 2026-03-31 | $74.40M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $75.80M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $71.50M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $56.30M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $58.30M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $65.10M 10-K · filed 2025-03-27 | |
| 2024-09-30 | $71.70M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $41.30M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $39.10M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $40.60M 10-K · filed 2024-03-19 | |
| 2023-09-30 | $42.30M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $24.10M 10-Q · filed 2023-08-10 | |
| 2022-12-31 | $23.30M 10-K · filed 2023-03-22 | |
| 2022-09-30 | $28.10M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $21.80M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $24.50M 10-Q · filed 2023-05-04 | $20.40M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $20.20M 10-K · filed 2022-03-03 | |
| 2021-09-30 | $5.40M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |